CD68 and classic Hodgkin lymphoma: A phase II clinical trial of CS1001 (PD-L1 inhibitor) of five relapsed or refractory (R/R) cHL elucidated that multiplex immunofluorescence staining was less intense for CD163 than CD68 (20).However, scholars from Korea found that CD163 is a better prognostic marker of macrophages in cHL (21).